Study design.

<p>Study design.</p

Anti-Sh28GST antibody levels in healthy adult volunteers after administration of rSh28GST 100 µg.

a<p>Specific Ig antibody levels are expressed as the mean of individual titer (± SEM). Number of responders after vaccination is indicated in parentheses.</p>b<p>Day of Sh28GST administration (D₀; D₂₈; D₁₅₀).</p>*<p>Significantly different (P<0.05) compared to D₀ (comparison of mean using the Wilcoxon test).</p>**<p>Significantly different (P<0.05) compared to D₁₅₀ (comparison of mean using the Wilcoxon test).</p

Specific IgG1 production and inhibition of enzymatic activity of rSh28GST by sera of vaccinated volunteers.

<p>Adult human volunteers received three administrations of rSh28GST of 100 µg respectively at D0, D28 and D150. IgG1 production is expressed as mean +/− SEM of titers at each time. Titer was defined as the highest dilution yielding an absorbance three times above background. Enzymatic inhibition is expressed in % (histograms). Percentage of inhibition was calculated by the ratio GST activity after serum incubation to GST activity control. This value was considered significantly positive above 10%.</p

Anti-Sh28GST antibody levels in healthy adult volunteers after administration of Alum (comparator group).

a<p>Specific Ig antibody levels are expressed as the mean of individual titer (± SEM). Number of responders after vaccination is indicated in parentheses.</p>b<p>Day of comparator administration (D₀; D₂₈; D₁₅₀).</p

Main baseline laboratory results.

<p>Abbreviations: WBC, white blood cell count; PTT, partial thromboplastin time; ALT, alanine aminotransferase; AST, aspartate aminotransferase. Data are presented as mean ± standard deviation.</p>*<p>Local laboratory values. All other biological tests were in normal ranges.</p

Anti-PT seroprevalence at T1 in all villages according to age category.

a<p>Chi-square test has been performed.</p>b<p>Kruskal-Wallis test between IgG responses according to the villages.</p>c<p>Mann-Whitney test has been performed for children of the same villages.</p

Seroprevalence of anti-PT IgG concentrations according to the village and visit for children younger (panel A) and older than 3 years (panel B).

<p>Chi-square test between seropositive children (anti-PT IgG concentration >30 IU/ml) and seronegative children at each visit within villages: panel A.: Agniam, <b>p = 0.3588</b>; Fanaye, p = 0.5227; Niandane, p = 0.4056; Pendao, p = 0.4276; Guédé, p = 0.9928; panel B.: Agniam, <b>p<0.0008</b>; Fanaye, p = 0.7641; Niandane, p = 0.2280; Pendao, p = 0.3292; Guédé, p = 0.1754.</p

Description of the cohort at the beginning of the survey (T1).

a<p>ANOVA test of age differences between children of all villages, and between ages of children of all villages according to their vaccination status.</p>b<p>Chi-square test to assess the gender distribution among villages and distribution of children within villages according to their vaccination status.</p><p>2 children were not vaccinated, one from Fanaye, and the other from Pendao.</p

Flow of participants through the study.

<p>Flow of participants through the study.</p

PT-IgG >30 IU/ml at T1 according to age categories and villages.

<p>Percentages of children with PT-IgG >30 IU/ml at the first visit in every village.</p><p>Total number of children within age category is in brackets.</p